Still digesting the Q, and having trouble reconciling the

New Post Public Reply Private Reply Replies (1) Message Board
Faustus sox0407 #45644
571
Still digesting the Q, and having trouble reconciling the sale price of the stock:

8M shares for $2M = .25 / share.....?

According to the "2017" sales agreement with Aspire:

Quote:
PLAN OF DISTRIBUTION

We entered into the Purchase Agreement with Aspire Capital on September 6, 2017. In consideration for entering into the Purchase Agreement, we issued 300,000 Commitment Shares to Aspire Capital. The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, Aspire Capital is irrevocably committed to purchase up to an aggregate of $30 million of shares of our common stock over the 36-month term of the Purchase Agreement, of which we have previously sold approximately $1.5 million as of the date of this prospectus supplement.

On any business day over the 36-month term of the Purchase Agreement (until September 7, 2020), we have the right, in our sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase up to 200,000 Purchase Shares per business day; however, no sale pursuant to such a Purchase Notice may exceed five hundred thousand dollars ($500,000) per business day, unless we and Aspire Capital mutually agree. We and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an additional 2,000,000 Purchase Shares per business day. The purchase price per Purchase Share pursuant to such Purchase Notice (the “Purchase Price”) is the lower of (i) the lowest sale price for our common stock on the date of sale; or (ii) the average of the three lowest closing sale prices for our common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date. The applicable Purchase Price will be determined prior to delivery of any Purchase Notice.

In addition, on any date on which we submit a Purchase Notice to Aspire Capital for at least 200,000 Purchase Shares, we also have the right, in our sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of our common stock equal to up to 30% of the aggregate shares of common stock traded on the next business day (the “VWAP Purchase Date”), subject to a maximum number of shares determined by us (the “VWAP Purchase Share Volume Maximum”). The purchase price per Purchase Share pursuant to such VWAP Purchase Notice (the “VWAP Purchase Price”) shall be 95% of the volume weighted average price for our common stock traded on (i) the VWAP Purchase Date if the aggregate shares to be purchased on that date does not exceed the VWAP Purchase Share Volume Maximum, or (ii) the portion of such business day until such time as the aggregate shares to be purchased will equal the VWAP Purchase Share Volume Maximum. Further, if on the VWAP Purchase Date the sale price of our common stock falls below the greater of (i) 80% of the closing price of our common stock on the business day immediately preceding the VWAP Purchase Date or (ii) the price set by us in the VWAP Purchase Notice (the “VWAP Minimum Price Threshold”), the VWAP Purchase Amount will be determined using the percentage in the VWAP Purchase Notice of the total shares traded for such portion of the VWAP Purchase Date prior to the time that the sale price of our common stock fell below the VWAP Minimum Price Threshold and the VWAP Purchase Price will be 95% of the volume weighted average price of our common stock sold during such portion of the VWAP Purchase Date prior to the time that the sale price of our common stock fell below the VWAP Minimum Price Threshold.

The number of Purchase Shares covered by and timing of each Purchase Notice or VWAP Purchase Notice are determined by the Company, at our sole discretion. Aspire Capital has no right to require any sales by us, but is obligated to make purchases from us as we direct in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. We did not pay any additional amounts to reimburse or otherwise compensate Aspire Capital in connection with the transaction. The Purchase Agreement may be terminated by us at any time, at our discretion, without any penalty or cost to us.

Does any formula listed here allow Aspire to buy shares at a 29% discount to the 52-week low (.352)? I distinctly remember Leo stating that the company would be telling Aspire the prices at which they would have to buy the stock, which set the old agreement apart from common convertible (floorless) debentures that encourage death spirals.....

I'm also still chewing on this statement from the most recent Q:
Quote:
Accordingly, the Company’s planned operations, including total budgeted expenditures of approximately $12.2 million for the next twelve months, raise doubt about its ability to continue as a going concern.

Am I reading that right? They intend on having to raise another $9M over the next 12 months?

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BMO's Strategic Exit: Transportation Finance Sale

Updated Category News Views 50

A Major Shift in BMO’s Strategic Direction When it comes to banking, BMO ain't playing small ball. They've just doubled down on their decision to part ways with their Transportation Finance and Vendor Finance operations, selling off a hefty part of these portfolios to Stonepeak. Now, that might sound like a mouthful, but hang tight, the nitty-gritty's where it gets...

Continue Reading
Bambusa Therapeutics: IPO Priced At $16, Shares On Nasdaq

Updated Category News Views 70

How Does Bambusa Therapeutics Stack Up? Well, here we go again in the biotech bonanza, folks. Bambusa Therapeutics is stepping onto the stage with their shiny new upsized IPO, offering a whopping 10,555,555 shares at sixteen bucks a pop. That's real money, coming in at $168,888,880 in gross proceeds if everything goes according to plan. Seems like a hefty sum, but in this...

Continue Reading
Farrin Firm Stands Out Again in Triangle's Fast 50

Updated Category News Views 50

Law Offices of James Scott Farrin in the Spotlight Another triumph for the Law Offices of James Scott Farrin. Not a newbie to recognition, this marks the third time in a row they've landed on the 'Triangle Business Journal's' esteemed 'Fast 50' list. They're the sole law firm among the Triangle's 50 fastest-growing private companies, making waves in a sea usually...

Continue Reading
Sohu.com Poised for Q3 2026 Earnings Report Soon

Updated Category News Views 59

Sohu.com Gears Up for Third Quarter Earnings Reveal Sohu.com Limited, the old guard of China's digital media scene, is gearing up to spill the beans on their third quarter 2026 financial results. Set to land on our desk on November 9 before U.S. markets get a whiff of morning coffee, this report might have a few tricks or tremors hiding in its pages. Conference Call to...

Continue Reading
Jay Group Expands to Houston with New Fulfillment Hub

Updated Category News Views 67

Jay Group's Bold Move in the Logistics Arena In a no-holds-barred expansion, Jay Group's got themselves a brand new sprawling 250,000-square-foot fulfillment hub deep in the heart of Houston. Now, folks, this isn’t just another warehouse. We're talking a 3PL powerhouse that allows coast-to-coast delivery, hitting 90% of U.S. consumers in just a couple of days. If you're...

Continue Reading
wagamama Spruces Up U.S. Market with mamago Launch

Updated Category News Views 70

What's Cooking at wagamama with mamago? Here comes wagamama, striding into the American dining scene with that familiar bold Pan-Asian flair, now offering more than just a seat at their tables. The fresh move to a direct-to-door model dubbed ‘mamago’ ushers in an era where their signature dishes don't just seduce your taste buds at their restaurants. Nope, they are...

Continue Reading
Life Time's Q3 2026 Results Highlight Solid Growth

Updated Category News Views 49

Life Time Rolls On With Strong Q3 Performance Sometimes the market hands you pure gold, and that's what Life Time (NYSE: LTH) has right now. They didn't just have a decent quarter; they outright nailed it with a $893.5 million total revenue haul—a hefty 14.2% rise from the prior year. What's driving this ship? Solid growth in membership dues and dynamic personal...

Continue Reading
SCI Faces Investigation After Earnings Downgrade

Updated Category News Views 23

SCI's Rough Ride: Investors Brace for Impact There's nothing like waking up to find the stock you were banking on took a nosedive while you were dreaming of dividends. Service Corporation International (NYSE: SCI) sure gave shareholders more of a nightmare than a dream, slashing its earnings forecast for 2026 and watching its stock crumble by about 11.6% on October 29....

Continue Reading
MUFG Debuts VAM for Streamlined Treasury Ops

Updated Category News Views 47

MUFG's Bold Move into Digital Liquidity Alright, let's dive into MUFG's latest shake-up, and boy, it's no small fry. This Japanese financial giant's got its eyes set on transforming how businesses handle their cash with what they're calling Virtual Account Management, or VAM - a fancy name for a digital liquidity tool that's looking to cut the clutter of multiple bank...

Continue Reading
Modular Building Boom Shakes Up Asian Construction

Updated Category News Views 45

Building the Future, One Module at a Time What's ticking in the world of construction? Modular buildings, my friends. They're generating buzz at the Fourth Linyi Mall International Buyers Conference held last week, and for good reasons. If you're not following, China is rolling out prefabricated houses like they're the next big thing since sliced bread, leaving buyers in...

Continue Reading

Top 5 Most Recently Viewed Articles

Pikangikum First Nation Unveils Their Inspiring Elders' Complex

Updated Category News Views 532

Celebrating the New Knowledge Keepers Elders' Complex Everyone deserves comfort and access to essential healthcare services close to home, and the opening of the Knowledge Keepers Elders' Complex symbolizes just that for the Pikangikum First Nation. By collaborating with Indigenous Services Canada and various partners, this community is committed to ensuring that their...

Continue Reading
Bath Haus Unveils Innovative Filtered Tub Spout for Wellness

Updated Category News Views 187

Introducing the Filtered Tub Spout by Bath Haus Bath Haus has just unveiled its innovative Filtered Tub Spout, a groundbreaking product that promises to transform bath time for enthusiasts all around. This smart design directly tackles the persistent issue of contaminants in bathwater, offering a solution that’s both practical and vital. A Healthier Bathing Experience...

Continue Reading
iRobot's 2024 Financial Results: Insights and Future Growth

Updated Category News Views 258

iRobot's Preliminary Financial Results for 2024 iRobot Corp. (NASDAQ: IRBT), a prominent player in the consumer robotics sector, has announced its preliminary financial results for the fourth quarter of the fiscal year. Despite facing challenges, the company showcased resilience and strategic planning to foster future growth. Overview of Financial Performance According to...

Continue Reading
Transformative Journey: City Lights Home Buyers Assists Family

Updated Category News Views 211

Overcoming Probate Challenges with City Lights Home Buyers Every homeowner faces moments of challenge, but for one Muskegon resident, these hurdles felt insurmountable. Secrest found herself overwhelmed, living in a property tied up in the probate process. Faced with a distressed home she couldn't maintain, she reached out for help—and that’s when City Lights Home...

Continue Reading
Valitor Welcomes Gregory Kunst as New CEO to Lead Growth

Updated Category News Views 277

Valitor Appoints New Chief Executive Officer Gregory D. Kunst In a significant move for the biotechnology field, Valitor has appointed Gregory D. Kunst as its new chief executive officer. Valitor, a pioneering company focused on creating innovative ophthalmic medicines, looks forward to leveraging Kunst's extensive experience in the industry to drive growth and...

Continue Reading